Travere Therapeutics (TVTX) Assets Average (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Assets Average came in at $580.2 million in Q1 2026, up 1.53% YoY from $571.5 million in Q1 2025, and up 1.45% on a QoQ basis from $571.9 million in Q4 2025.
Travere Therapeutics (TVTX) Assets Average (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of Assets Average data on file, last reported at $580.2 million in Q1 2026.
- Quarterly Assets Average rose 1.53% year-over-year to $580.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $580.2 million (up 1.53% YoY) and the FY2025 annual result came in at $599.7 million, down 13.28% from the prior year.
- Assets Average advanced to $580.2 million in Q1 2026, from $571.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $810.9 million in Q4 2023 to a low of $527.8 million in Q3 2024.
- A 5-year average of $670.6 million and a median of $699.4 million in 2022 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average increased 17.03% — and 2024, when it tumbled 32.74%.
- Tracing TVTX's Assets Average over 5 years: stood at $699.4 million in 2022, then gained by 15.94% to $810.9 million in 2023, then plunged by 32.26% to $549.3 million in 2024, then advanced by 4.12% to $571.9 million in 2025, then climbed by 1.45% to $580.2 million in 2026.
- The last three Assets Average figures came in at $580.2 million (Q1 2026), $571.9 million (Q4 2025), and $546.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 677.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 677.27 Mn |
| Mar 31, 2026 | 580.19 Mn |
| Dec 31, 2025 | 571.89 Mn |
| Sep 30, 2025 | 546.95 Mn |
| Jun 30, 2025 | 552.05 Mn |
| Mar 31, 2025 | 571.46 Mn |
| Dec 31, 2024 | 549.27 Mn |
| Sep 30, 2024 | 527.77 Mn |
| Jun 30, 2024 | 607.33 Mn |
| Mar 31, 2024 | 726.23 Mn |
| Dec 31, 2023 | 810.88 Mn |
| Sep 30, 2023 | 784.64 Mn |
| Jun 30, 2023 | 772.33 Mn |
| Mar 31, 2023 | 740.41 Mn |
| Dec 31, 2022 | 699.40 Mn |
| Sep 30, 2022 | 752.85 Mn |
| Jun 30, 2022 | 803.95 Mn |
| Mar 31, 2022 | 802.52 Mn |
| Dec 31, 2021 | 775.85 Mn |
| Sep 30, 2021 | 760.92 Mn |